Phase 4 Peripheral Arterial Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been recently diagnosed with Multiple Myeloma (MM) based on standard international diagnostic guidelines
- People who are currently being treated with a chemotherapy regimen called VRd, which includes a drug called bortezomib
- People who are relatively well and able to carry out daily activities, as measured by a standard medical performance scale (ECOG score below 2)
- People whose blood cell counts and hemoglobin levels are within acceptable ranges (confirm with trial site for exact values)
- People whose liver and kidney function test results are within acceptable ranges (confirm with trial site for exact values)
Who may not be able to join:
- People who have been treated with certain nerve-damaging medications (such as cisplatin, vincristine, taxanes, or similar drugs) within the past 6 months
- People currently taking antioxidant vitamins (such as vitamins A, C, or E), anti-seizure medications, tricyclic antidepressants, or medications used for nerve pain (such as gabapentin, lamotrigine, or carbamazepine)
- People who already have nerve damage caused by other conditions, such as diabetes, thyroid problems, autoimmune diseases, or hepatitis C
- People living with inflammatory conditions such as ulcerative colitis or rheumatoid arthritis
- People with conditions linked to increased bodily stress, including smoking, tuberculosis, or obesity
- People with active liver disease, such as cirrhosis, fatty liver, or hepatitis C
- People with muscle disease (myopathy)
- People who have or have had another type of cancer
- People with kidney problems, including those with severe kidney disease or those currently on dialysis
- People with gallbladder disease or gallstones
- People who are pregnant or breastfeeding
- People with a known allergy to fenofibrate medications
- People currently taking certain medications that may interact with the trial drug, including statins, colchicine, ciprofibrate, idelalisib, certain anti-seizure drugs, certain antifungal or antibiotic drugs, or certain medications that bind strongly to proteins in the blood such as warfarin, sulfonamides, or oral diabetes medications (confirm with trial site for the full list)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ashraf M Alaa, BSc of clinical pharmacy, clinical pharmacy departement - Faculty of Pharmacy - Tanta University
Phone: +201011301390
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change in percentage of patients with peripheral neuropathy grade ≥ 2 with the variation of both 12-item neurotoxicity questionnaire (Ntx-12) total score and NCI-CTCAE, v5.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.